Primary hyperaldosteronism historical perspective
|
Primary hyperaldosteronism Microchapters |
|
Differentiating Primary Hyperaldosteronism from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Primary hyperaldosteronism historical perspective On the Web |
|
American Roentgen Ray Society Images of Primary hyperaldosteronism historical perspective |
|
Primary hyperaldosteronism historical perspective in the news |
|
Risk calculators and risk factors for Primary hyperaldosteronism historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Historical Perspective
- Primary hyperaldosteronism (Conn's syndrome) was described for the first time by the Polish internist Michał Lityński.[1]
- In 1955, Dr Jerome W. Conn the American endocrinologist first described the condition and named it Conn's syndrome. [2][3]
- From 1960s to early 1970s, its techniques of diagnosis and treatment were greatly improved by the availability of spironolactone, realization of the renin-angiotensin-aldosterone system, and progress in laboratory tests and adrenal venous sampling.
- On October 19, 1964, Jerome W. Conn, Edwin L. Cohen and David R. Rovner differentiated between primary and secondary aldosteronism in hypertensive disease.[4]
- In 1970s, notwithstanding the extensive application of modern imaging modalities, such as CT scanning, adrenal venous sampling and steroid analysis have remained to be the most accurate and reliable localization method.
- From 1980s, more and more patients with primary aldosteronism were screened out from the hypertensive population by plasma renin activity/plasma aldosterone concentration ratio and cured by surgical interventions; laparoscopic unilateral adrenalectomy has become the generally accepted golden standard of operation.
References
- ↑ Kucharz EJ (2007). "[Michał Lityński--a forgotten author of the first description on primary hyperaldosteronism]". Pol. Arch. Med. Wewn. (in Polish). 117 (1–2): 57–8. PMID 17642209.
- ↑ Conn JW, Louis LH. Primary aldosteronism: a new clinical entity. Trans Assoc Am Physicians 1955;68:215-31; discussion, 231-3. PMID 13299331.
- ↑ "Grand Rounds: Primary Aldosteronism, Beyond Conn's Syndrome | Clinical Correlations".
- ↑ Conn JW, Cohen EL, Rovner DR (1985). "Landmark article Oct 19, 1964: Suppression of plasma renin activity in primary aldosteronism. Distinguishing primary from secondary aldosteronism in hypertensive disease. By Jerome W. Conn, Edwin L. Cohen and David R. Rovner". JAMA. 253 (4): 558–66. PMID 3881606.